17 hours Ago By ABMN Staff
KLP Kapitalforvaltning AS purchased a new stake in shares of Vera Therapeutics, Inc. ( NASDAQ:VERA – Free Report ) in the fourth quarter, Holdings Channel reports. The firm purchased 10,200 shares of the company’s stock, valued at approximately $431,000.
Several other institutional investors have also added to or reduced their stakes in VERA. Jennison Associates LLC boosted its holdings in shares of Vera Therapeutics by 82.0% during the fourth quarter.
Jennison Associates LLC now owns 813,861 shares of the company’s stock worth $34,418,000 after purchasing an additional 366,763 shares during the period. Victory Capital Management Inc. increased its stake in shares of Vera Therapeutics by 515.
0% during the fourth quarter. Victory Capital Management Inc. now owns 235,267 shares of the company’s stock valued at $9,949,000 after buying an additional 197,014 shares during the period.
Lord Abbett & CO. LLC increased its stake in shares of Vera Therapeutics by 41.1% during the third quarter.
Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock valued at $18,830,000 after buying an additional 124,197 shares during the period. Pier Capital LLC bought a new position in shares of Vera Therapeutics during the third quarter valued at approximately $4,573,000.
Finally, Raymond James Financial Inc. purchased a new stake in Vera Therapeutics in the fourth quarter worth $2,948,000. Hedge funds and other institutional investors own 99.
21% of the company’s stock. Vera Therapeutics Price Performance Shares of VERA opened at $21.31 on Friday.
Vera Therapeutics, Inc. has a fifty-two week low of $20.27 and a fifty-two week high of $51.
61. The firm’s 50-day simple moving average is $29.82 and its two-hundred day simple moving average is $38.
35. The stock has a market cap of $1.36 billion, a PE ratio of -8.
16 and a beta of 1.17. The company has a debt-to-equity ratio of 0.
17, a quick ratio of 13.76 and a current ratio of 13.76.
Wall Street Analyst Weigh In VERA has been the topic of a number of research analyst reports. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.
00 price objective on the stock. Guggenheim boosted their price target on shares of Vera Therapeutics from $59.00 to $61.
00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.
00 price target for the company. Finally, JPMorgan Chase & Co. cut their price objective on Vera Therapeutics from $77.
00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock.
According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $64.67.
View Our Latest Research Report on Vera Therapeutics Insider Transactions at Vera Therapeutics In related news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.
00. Following the transaction, the chief executive officer now owns 143,603 shares in the company, valued at $5,993,989.22.
The trade was a 10.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink .
Insiders own 21.70% of the company’s stock. Vera Therapeutics Company Profile ( Free Report ) Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. Featured Stories Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc.
( NASDAQ:VERA – Free Report ). Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
